Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | TEK | Q02763 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17187889 | 0.80 | HTR2A (0.31) | CYP2D6 | |
| SCHEMBL18428147 | 0.74 | — | — | |
| SCHEMBL18428143 | 0.70 | ALOX5 (0.48) | MTNR1AMTNR1BEGLN2EGLN1 | |
| SCHEMBL6410573 | 0.67 | MTNR1A (0.47) | MTNR1ANQO2 | |
| SCHEMBL6582651 | 0.67 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6433632 | 0.67 | MTNR1A (0.47) | MTNR1AEGLN1NQO2 | |
| SCHEMBL6432839 | 0.67 | MTNR1A (0.50) | MTNR1AMTNR1BNQO2 | |
| Lithium SCHEMBL6433640 | 0.67 | MTNR1A (0.47) | MTNR1AEGLN1NQO2 | |
| SCHEMBL30260100 | 0.67 | KDM4E (0.33) | CYP2D6 | |
| SCHEMBL31670075 | 0.66 | CYP2A6 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134392-B1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-9840482-B2 | Sulfonamide derivatives and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20170037017-A1 | Sulfonamide Derivatives And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037017-A1 | Sulfonamide Derivatives And Pharmaceutical Applications Thereof | HTR6, SLC6A4, HTR2A | MTNR1A 48/4885MTNR1B 99/4885EGLN2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.